Late-onset seropositive Isaacs' syndrome after Guillain-Barré syndrome.
Acquired neuromyotonia, or Isaacs' syndrome, has been described in combination with a variety of other autoimmune disorders; however there has never been a report of seropositive Isaacs' syndrome in a patient with a history of Guillain-Barré syndrome (GBS). Both conditions involve antibody-mediated autoimmune effects on the peripheral nervous system, although the clinical manifestations are quite different. We present a man who experienced an episode of GBS at the age of 21 and subsequently developed Isaacs' syndrome at the age of 24 which was positive for anti-voltage-gated potassium channel (VGKC) antibodies. When treated with intravenous immunoglobulins (IVIg) he developed an eczematous rash that differed markedly in pattern and duration from the usual presentation for this IVIg reaction.
Myers
Kenneth A
KA
Faculty of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, Alberta, Canada.
Baker
Steven K
SK
D000927:Anticonvulsants / Q000627:therapeutic use; D001323:Autoantibodies / Q000032:analysis / Q000097:blood*; D018491:Dopamine Agonists / Q000627:therapeutic use; D004485:Eczema / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D005076:Exanthema / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology; D020275:Guillain-Barre Syndrome / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D007049:Iatrogenic Disease; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D007155:Immunologic Factors / Q000009:adverse effects; D020386:Isaacs Syndrome / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D018482:Muscle, Skeletal / Q000276:immunology / Q000503:physiopathology; D010243:Paralysis / Q000209:etiology; D010525:Peripheral Nerves / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D024642:Potassium Channels, Voltage-Gated / Q000276:immunology*; D013035:Spasm / Q000276:immunology / Q000503:physiopathology; D013745:Tetanus Toxoid / Q000009:adverse effects
D000927:Anticonvulsants; D001323:Autoantibodies; D018491:Dopamine Agonists; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D024642:Potassium Channels, Voltage-Gated; D013745:Tetanus Toxoid